Avacta® has exclusive rights over the Affimer® technology intellectual property through a number of granted global patents and patents pending. The company continues to broaden its Affimer® platform intellectual property, as well as generating application specific know-how and patentable inventions, through active R&D programmes.
This simple intellectual property position, in addition to the company’s unique know-how and experience of the Affimer® technology, lies at the core of our arrangements to develop innovative therapeutics, research tools and diagnostics.
- Download our trademarks summary.
For more information on Avacta’s IP portfolio, please contact us.